This article was originally published in Pharmaceutical Approvals Monthly
AstraZeneca's Iressa (gefitinib) is slated for review by FDA's Oncologic Drugs Advisory Committee Sept. 24. A rolling NDA for use of the epidermal growth factor receptor/tyrosine kinase inhibitor for treatment of non-small cell lung cancer was completed Aug. 5. The NDA contains two Phase II monotherapy studies in approximately 400 patients to support efficacy. Recent data from the Phase III INTACT 1 and 2 mortality trials, which examined Iressa in combination with standard platinum-based chemotherapy, failed to show a benefit in survival or symptom improvement. In announcing the results, the firm indicated that FDA could change the agenda for the Sept. 24 ODAC meeting. AstraZeneca plans to focus future studies on monotherapy use in sequential therapy regimens, with initial studies in the neoadjuvant settin
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.